Matinas BioPharma Holdings Inc (MTNB) Sees Large Decrease in Short Interest

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) was the recipient of a significant drop in short interest in January. As of January 12th, there was short interest totalling 1,331,591 shares, a drop of 9.1% from the December 29th total of 1,464,128 shares. Currently, 1.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 121,996 shares, the short-interest ratio is currently 10.9 days.

Matinas BioPharma (NYSEAMERICAN:MTNB) opened at $1.14 on Friday. The firm has a market cap of $105.96, a PE ratio of -3.08 and a beta of 0.69. Matinas BioPharma has a 52 week low of $1.01 and a 52 week high of $3.99.

Matinas BioPharma (NYSEAMERICAN:MTNB) last issued its earnings results on Wednesday, November 15th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. Matinas BioPharma had a negative net margin of 7,558.92% and a negative return on equity of 195.09%. The company had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.05 million.

A hedge fund recently bought a new stake in Matinas BioPharma stock. Yellowstone Partners LLC bought a new position in shares of Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 143,914 shares of the company’s stock, valued at approximately $190,000. Yellowstone Partners LLC owned 0.16% of Matinas BioPharma at the end of the most recent reporting period.

TRADEMARK VIOLATION NOTICE: This news story was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at

About Matinas BioPharma

Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.

Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit